Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy

Obstetrics and Gynecology

Volumn 106, Issue 3, 2005, Pages 548-552

  Wolfberg, Adam J ^a   Berkowitz, Ross S ^b   Goldstein, Donald P ^b   Feltmate, Colleen ^b   Lieberman, Ellice ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN;

ADULT; ARTICLE; CANCER RISK; COHORT ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HUMAN; HYDATIDIFORM MOLE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL RISK; TROPHOBLASTIC TUMOR; VACUUM EXTRACTION;

EID: 23944488795     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000174583.51617.25     Document Type: Article

References (16)

1. Wolfberg AJ, Feltmate C, Goldstein DP, Berkowitz RS, Lieberman E. Low risk of relapse after achieving undetectable hCG levels in women with complete molar pregnancy. Obstet Gynecol 2004;104:551-4.
2. Lurain JR, Brewer JI, Torok EE, Halpern B. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol 1983;145:591-5.
3. Kohorn EI. Hydatidiform mole and gestational trophoblastic disease in Southern Connecticut. Obstet Gynecol 1982;59: 78-84.
4. Curry SL, Hammond CB, Tyrey L, Creasman WT, Parker RT. Hydatidiform mole: diagnosis, management, and long-term followup of 347 patients. Obstet Gynecol 1975;45:1-8.
5. Yuen BH, Cannon W. Molar pregnancy in British Columbia: estimated incidence and post-evacuation regression patterns of the beta subunit of human chorionic gonadotropin. Am J Obstet Gynecol 1981;139:316-9.
6. Goldstein DP, Berkowitz RS, Bernstein MR. Management of molar pregnancy. J Reprod Med 1981;26:208-12.
7. Ayhan A, Tuncer ZS, Halilzade H, Kucukali T, Predictors of persistent disease in women with complete hydatidiform mole. J Reprod Med 1996. 41:591-4.
8. Berkowitz R, Ozturk M, Goldstein D, Bernstein M, Hill L, WandsJR. Human chorionic gonadotropin and free subunits' serum levels in patients with partial and complete hydatidiform moles. Obstet Gynecol. 1989;74:212-5.
9. Smith EB, Szulman AE, Hinshaw W, Tyrey L, Surti U, Hammond CB. Human chorionic gonadotropin levels in complete and partial hydatidiform moles and in nonmolar abortuses. Am J Obstet Gynecol. 1984;149:129-32.
10. Morrow CP, Kletzky OA, Disaia PJ, Townsend DE, Mishell DR, Nakamura RM. Clinical and laboratory correlates of molar pregnancy and trophoblastic disease. Am J Obstet Gynecol 1977;128:424-30.
11. Schlaerth JB, Morrow CP, Kletzky OA, Nalick RH, D'Ablaing GA. Prognostic characteristics of serum human chorionic gonadotropin titer regression following molar pregnancy. Obstet Gynecol 1981;58:478-82.
12. Shigematsu T, Kamura T, Saito T, Kaku T, Nakano H, Kinugawa N. Identification of persistent trophoblastic diseases based on a human chorionic gonadotropin regression curve by means of a stepwise piecewise linear regression analysis after the evacuation of uneventful moles. Gynecol Oncol 1998;71: 376-80.
13. Berkowitz RS, Goldstein DP. Chorionic tumors. N Engl J Med 1996;335:1740-8.
14. Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med 2002;47:445-50.
15. Xia ZF, Song HZ, Tang MY. Risk of malignancy and prognosis using a provisional scoring system in hydatidiform mole. Chin Med J 1980;93:605-12.
16. Berkowitz RS, Bernstein MR, Laborde O, Goldstein DP. Subsequent pregnancy experience in patients with gestational trophoblastic disease: New England Trophoblastic Disease Center, 1965-1992. J Reprod Med 1994;39:228-32.